IVERIC bio, Inc. (ISEE) Report Analysis
Corporate Events
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 3000E Growth Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 3000E Growth Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 2000 Value Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 2000 Value Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 3000 Value Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 3000 Value Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Growth Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Growth Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 2500 Value Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 2500 Value Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Small Cap Comp Value Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Small Cap Comp Value Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Value Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 3000E Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 3000E Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 3000E Value Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell 3000E Value Index
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Index
2022-06-24 00:00:00
IVERIC bio, Inc.(NasdaqGS:ISEE) dropped from Russell Microcap Index
IVERIC bio, Inc. Announces Presentation of Post-Hoc Analysis At Macula Society from Gather1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
2022-06-10 11:00:00
IVERIC bio, Inc. announced a post-hoc analysis from the Zimura® (avacincaptad pegol) GATHER1 clinical trial which explored enhanced Optical Coherence Tomography (OCT) image analysis to examine the effect of Zimura on change in Ellipsoid Zone (EZ) integrity and growth of OCT-measured geographic atrophy (GA), and to examine the correlation between Fundus Autofluorescence (FAF)-measured and OCT-measured GA progression in the GATHER1 trial. The analysis was presented by Justis P. Ehlers, MD, Cole Eye Institute, Cleveland Clinic, at the Macula Society Meeting in Berlin, Germany. The results of the post-hoc analysis showed that OCT-measured GA area strongly correlated with FAF-measured GA area, with minimal average differences in GA area between modalities. As typically used in GA clinical trials, FAF was utilized to measure GA in the GATHER1 clinical trial. A 30% reduction was observed in OCT-measured GA growth with Zimura at 12 months, which is consistent with findings using FAF-measured GA growth in GATHER1. In addition, a 22% reduction in progressive EZ loss/attenuation at 18 months was observed with Zimura compared to sham. The analyses were performed in collaboration with The Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, at the Cole Eye Institute, Cleveland Clinic, and included macular cube OCT scans from the Zimura 2 mg and 4 mg groups (n=150), and sham group (n=110). The scans were loaded into a machine-learning enhanced OCT mapping software and analyzed for integrity of the outer retinal layers, including the EZ, as well as the sub-RPE compartment. No additional safety analysis was performed as part of the post-hoc analysis.
IVERIC bio, Inc. Presents at UBS Global Healthcare Conference, May-23-2022 10:45 AM
2022-05-17 09:30:00
IVERIC bio, Inc. Presents at UBS Global Healthcare Conference, May-23-2022 10:45 AM. Venue: Lotte New York Palace, New York City, New York, United States. Speakers: Pravin U. Dugel, President.
IVERIC bio, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM
2022-05-16 09:02:00
IVERIC bio, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 07:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States. Speakers: Pravin U. Dugel, President.
IVERIC bio, Inc., Q1 2022 Earnings Call, May 04, 2022
2022-04-27 12:00:00
IVERIC bio, Inc., Q1 2022 Earnings Call, May 04, 2022
IVERIC bio, Inc. to Report Q1, 2022 Results on May 04, 2022
2022-04-27 12:00:00
IVERIC bio, Inc. announced that they will report Q1, 2022 results on May 04, 2022
IVERIC bio, Inc. Presents at B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr-28-2022 09:00 AM
2022-04-26 12:00:00
IVERIC bio, Inc. Presents at B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr-28-2022 09:00 AM.
IVERIC bio, Inc. Presents at Wet AMD and DME Drug Development Summit, Apr-05-2022 through Apr-07-2022
2022-04-05 17:08:00
IVERIC bio, Inc. Presents at Wet AMD and DME Drug Development Summit, Apr-05-2022 through Apr-07-2022. Venue: Embassy Suites by Hilton Boston Logan Airport, 207 Porter St., Boston, Massachusetts, United States. Presentation Date & Speakers: Apr-06-2022, Dhaval Desai, Senior VP & Chief Development Officer.
Hanson Wade Limited, Wet AMD and DME Drug Development Summit, Apr 05, 2022 through Apr 07, 2022
2022-04-05 12:05:00
Hanson Wade Limited, Wet AMD and DME Drug Development Summit, Apr 05, 2022 through Apr 07, 2022. Venue: Embassy Suites by Hilton Boston Logan Airport, 207 Porter St., Boston, Massachusetts, United States.
IVERIC bio, Inc. Completes Retrospective Review of Choroidal Neovascularization
2022-04-04 10:56:00
IVERIC bio, Inc. working with an independent reading center, recently completed a retrospective review of the cases of choroidal neovascularization ("CNV") in the Zimura® (avacincaptad pegol) 2 mg group (n=67) from GATHER1, the Company's first pivotal clinical trial evaluating the safety and efficacy of Zimura for the treatment of geographic atrophy ("GA") secondary to age-related macular degeneration ("AMD"). As previously reported, the incidence of investigator reported CNV in the study eye in the Zimura 2 mg group in the completed GATHER1 clinical trial was six (6) patients (9.0%) at 12 months and eight (8) patients (11.9%) at 18 months. GATHER2, the Company's second pivotal clinical trial evaluating the safety and efficacy of Zimura 2 mg for the treatment of GA remains ongoing, with topline data expected to be available during the second half of 2022. The retrospective review was performed by the Center for Ocular Research and Evaluation (CORE) at Cole Eye Institute of the Cleveland Clinic (the "Reading Center"). As part of the retrospective review, the Reading Center read optical coherence tomography ("OCT") images for the eight (8) patients in the Zimura 2 mg group who developed CNV in the study eye. OCT is an ultra-high resolution imaging technology commonly used to visualize the retinal tissue. OCT is capable of rendering images in multiple dimensions and from multiple perspectives, including a cross-sectional view of the retina showing clearly defined layers of retinal tissue. OCT is the dominant imaging modality used by retinal specialists in the United States to diagnose, treat and follow patients with CNV. OCT images were read to determine the number of CNV cases that were (1) macular neovascularization ("MNV") (versus peripapillary neovascularization, where the neovascularization is located around the optic nerve and not encroaching on the macula) and (2) exudative MNV (versus non-exudative MNV). T he Reading Center classifies cases of MNV as exudative or non-exudative based on the following OCT criteria: Exudative MNV ("eMNV") is MNV that presents with new onset fluid in either the subretinal space or the intraretinal space. The subretinal space is the area on OCT between the retinal pigment epithelium ("RPE") and photoreceptor cells. The intraretinal space is the area on OCT containing the photoreceptors and other neurosensory cells of the retina. Non-exudative MNV ("neMNV") is neovascularization located in the macula but which does not present with new onset fluid in the subretinal or intraretinal spaces. In some cases, isolated fluid may be present in the sub-RPE space, which is the area between the RPE and Bruch's membrane, a layer of tissue directly beneath the RPE separating the RPE from the choroid. A case is also considered to be neMNV when the MNV may not be visible but both a double-layer sign and sub-RPE fluid are present. A double-layer sign is characterized by a shallow elevation of the RPE typically caused by the accumulation of fluid or debris in the sub-RPE space. The Reading Center also reviewed the baseline OCT images for all eight (8) patients looking for the presence of a double-layer sign at baseline. A study published in 2019 in the peer-reviewed journal Ophthalmology Retina found that the presence of a double-layer sign is correlated with the presence or development of neMNV in eyes with AMD, and clinical experience has shown that this type of neMNV often progresses to eMNV. Based on scientific literature and clinical understanding among the retinal community, the Company believes the presence of a double-layer sign on OCT is a useful biomarker to predict the future onset of cases of eMNV. In this retrospective review, the Reading Center found that among the six (6) GATHER1 patients who developed eMNV over 18 months, five (5) of those patients had a double-layer sign at baseline. The Reading Center also found that neither of the two GATHER1 patients who had neMNV at the 12-month and 18-month timepoints had a double-layer sign at baseline. For this retrospective review, OCT images were graded at the Reading Center by two masked, independent readers, with the gradings confirmed by two additional masked, independent senior readers. All OCT gradings for these patients were consistent among all readers. All of the readers remained masked to treatment condition throughout the review. The Company does not plan to report data comparing the growth of GA area in the study eye to the growth of GA area in the fellow eye among patients in the GATHER1 trial. The study eye is the eye that received study drug or sham during the trial, while the fellow eye is the patient's other eye. In the GATHER1 trial, one of the key ophthalmic inclusion criteria was the presence of GA in the study eye located in whole or in part within 1,500 microns of the fovea, the central portion of the macula, but which did not enter the foveal center point. These criteria did not apply to the fellow eye, and the Company has not collected measurements of the fellow eye that would enable it to determine which patients' fellow eyes would have met the study eye inclusion criteria. As the Company has previously discussed, it has been widely reported in scientific literature and observed in clinical trials that GA that is non-subfoveal (that has not impacted the foveal center), is positively correlated with a higher rate of GA area progression and growth as compared to GA that has reached the foveal center. For these reasons, the Company does not believe that a valid comparison between the growth of GA area in the study eye versus that in the fellow eye can be made for the GATHER1 trial.
B. Riley Securities, Inc., B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr 27, 2022 through Apr 28, 2022
2022-03-31 16:27:00
B. Riley Securities, Inc., B. Riley Securities's 2022 Virtual Neurology & Ophthalmology Conference, Apr 27, 2022 through Apr 28, 2022.
IVERIC bio, Inc., Annual General Meeting, May 12, 2022
2022-03-30 20:34:00
IVERIC bio, Inc., Annual General Meeting, May 12, 2022, at 12:30 US Eastern Standard Time. Agenda: To elect two class III directors of board of directors to serve until the 2025 annual meeting of stockholders or until their respective successors have been duly elected and qualified; to hold a non-binding, advisory vote to approve named executive officer compensation; to hold a non-binding, advisory vote on the frequency of future advisory votes to approve named executive officer compensation; to ratify the selection of Ernst & Young LLP as IVERIC’s independent registered public accounting firm for the fiscal year ending December 31, 2022; and to transact such other business as may properly come before the 2022 annual meeting or any adjournment or postponement thereof.
IVERIC bio, Inc. - Shareholder/Analyst Call
2022-03-30 20:34:00
AGM
UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022
2022-03-03 04:07:00
UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022. Venue: Lotte New York Palace, New York City, New York, United States.
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022
2022-02-28 18:21:00
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.
Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy
2022-02-11 13:00:00
IVERIC bio, Inc. announced a post-hoc analysis which evaluated various Geographic Atrophy (GA) growth parameters to explore the rate of disease progression within various regions in the fovea in a subset of patients from the GATHER1 Zimura® (avacincaptad pegol) Phase 3 clinical trial for the treatment of GA. The results of this subgroup analysis are consistent with the primary analysis results in the intent to treat population. The post-hoc analysis evaluated GA growth in five standardized regions in the retina for patients for whom images were available at relevant time points (n = 47 in the Zimura 2 mg group and n = 79 in the sham group). The five regions included the central foveal region, consisting of a 2 mm diameter circle around the foveal center point, and four quadrants, temporal, nasal, superior and inferior, in a concentric 8 mm diameter circle around the foveal center point. The accompanying schematic illustrates the five standardized regions. The accompanying graphs illustrate the results of the analysis that will be presented at the Angiogenesis, Exudation, and Degeneration 2022 meeting by Glenn J. Jaffe, MD, Director, Duke Reading Center Chief, Retina Division, Duke Eye Center, Robert Machemer Professor of Ophthalmology.
IVERIC bio, Inc. Appoints Tony Gibney as Executive Vice President and Chief Business and Strategy Officer
2021-12-13 22:08:00
IVERIC bio, Inc. announced the appointment of Tony Gibney to Executive Vice President and Chief Business and Strategy Officer, effective December 13, 2021. Mr. Gibney is an experienced biotechnology executive and former investment banker. Mr. Gibney brings over 25 years of experience dedicated to advising biotechnology companies in the U.S. and Europe on corporate matters such as business strategy, collaboration transactions, financings, and mergers and acquisitions. As a biotechnology executive, Mr. Gibney completed multiple strategic transactions, and was responsible for the execution of corporate, operational, and business development strategies. Most recently, Mr. Gibney served as Chief Financial Officer and Chief Business Officer at Fog Pharmaceuticals overseeing and driving the business development, strategy and finance functions of the company.
IVERIC bio, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 10:40 AM
2021-11-10 13:00:00
IVERIC bio, Inc. Presents at Stifel 2021 Virtual Healthcare Conference, Nov-16-2021 10:40 AM. Venue: New York, New York, United States. Speakers: Glenn P. Sblendorio, CEO & Director, Pravin U. Dugel, President.
IVERIC bio, Inc. has filed a Shelf Registration in the amount of $18.3 million.
2021-11-09 00:00:00
IVERIC bio, Inc. has filed a Shelf Registration in the amount of $18.3 million. Security Name: Common Stock Securities Offered: 1,000,000 Transaction Features: ESOP Related Offering
IVERIC bio, Inc. to Report Q3, 2021 Results on Nov 09, 2021
2021-11-02 12:00:00
IVERIC bio, Inc. announced that they will report Q3, 2021 results on Nov 09, 2021
IVERIC bio, Inc., Q3 2021 Earnings Call, Nov 09, 2021
2021-11-02 08:29:00
IVERIC bio, Inc., Q3 2021 Earnings Call, Nov 09, 2021
IVERIC bio, Inc. has filed a Shelf Registration.
2021-10-21 00:00:00
IVERIC bio, Inc. has filed a Shelf Registration. Security Name: Debt Securities Security Name: Common Stock Security Name: Preferred Stock Security Name: Warrants Security Name: Subscription Rights Security Name: Depositary Shares Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration
IVERIC bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.
2021-10-21 00:00:00
IVERIC bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: Common Stock Security Type: Common Stock
IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $150.75 million.
2021-10-21 00:00:00
IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $150.75 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,000,000 Price\Range: $16.75 Discount Per Security: $1.005
Certain Common Stock of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021.
2021-10-21 00:00:00
Certain Common Stock of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 21-DEC-2021. These Common Stock will be under lockup for 61 days starting from 21-OCT-2021 to 21-DEC-2021. Details: The directors and officers have agreed that, without the prior written consent of Morgan Stanley & Co. LLC and Cowen and Company, LLC on behalf of the underwriters, will not, during the period ending 60 days after the date of this prospectus offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned or any securities so owned convertible into or exercisable or exchangeable for shares of common stock, enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock or publicly disclose the intention to make any such offer, sale, pledge or disposition of shares of common stock; whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise.
IVERIC bio, Inc. Presents at 2nd Dry AMD Therapeutic Development Summit, Oct-19-2021
2021-10-12 18:27:00
IVERIC bio, Inc. Presents at 2nd Dry AMD Therapeutic Development Summit, Oct-19-2021 . Speakers: Dhaval Desai, Senior Vice-President & Chief Development Officer.
Hanson Wade Limited, 2nd Dry AMD Therapeutic Development Summit, Oct 19, 2021 through Oct 21, 2021
2021-10-12 06:27:00
Hanson Wade Limited, 2nd Dry AMD Therapeutic Development Summit, Oct 19, 2021 through Oct 21, 2021.
IVERIC bio, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 11:20 AM
2021-10-01 10:34:00
IVERIC bio, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 11:20 AM. Venue: Rancho Palos Verdes, California, United States. Speakers: Glenn P. Sblendorio, CEO & Director, Pravin U. Dugel, President.
IVERIC bio, Inc. Presents at Annual Ophthalmology Innovation Summit (OIS) Retina @ASRS Conference, Oct-07-2021 09:02 AM
2021-09-30 23:02:00
IVERIC bio, Inc. Presents at Annual Ophthalmology Innovation Summit (OIS) Retina @ASRS Conference, Oct-07-2021 09:02 AM. Venue: San Antonio, Texas, United States. Speakers: Pravin U. Dugel, President.
Healthegy, Inc., Annual Ophthalmology Innovation Summit (OIS) Retina @ASRS Conference, Oct 07, 2021
2021-09-30 20:05:00
Healthegy, Inc., Annual Ophthalmology Innovation Summit (OIS) Retina @ASRS Conference, Oct 07, 2021. Venue: San Antonio, Texas, United States.
IVERIC bio, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM
2021-09-10 20:17:00
IVERIC bio, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Pravin U. Dugel, President.
IVERIC bio, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021
2021-09-01 19:46:00
IVERIC bio, Inc. Presents at Citi’s 16th Annual BioPharma Virtual Conference, Sep-08-2021 . Venue: New York, United States.
IVERIC bio, Inc. Presents at H.C. Wainwright 2021 Virtual Ophthalmology Investor Conference, Aug-17-2021
2021-08-10 12:00:00
IVERIC bio, Inc. Presents at H.C. Wainwright 2021 Virtual Ophthalmology Investor Conference, Aug-17-2021. Presentation Date & Speakers: Aug-17-2021, Pravin U. Dugel, President.
IVERIC bio, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 08:00 AM
2021-08-04 20:05:00
IVERIC bio, Inc. Presents at 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug-11-2021 08:00 AM. Speakers: Pravin U. Dugel, President.
IVERIC bio Names Christopher Simms as Senior Vice President and Chief Commercial Officer, Effective August 2, 2021
2021-07-29 15:00:00
IVERIC bio reported the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2. Simms joins Iveric Bio from Novartis, where he successfully managed commercial operations for the U.S. Ophthalmics Franchise, launching BEOUV (brolucizumab injection) for wet age-related macular degeneration (AMD). Before Novartis, he served as marketing lead for the Genentech ophthalmology business which included creating a new brand positioning and launching a new campaign for Lucentis (ranibizumab injection).
IVERIC bio, Inc. to Report Q2, 2021 Results on Aug 04, 2021
2021-07-28 12:00:00
IVERIC bio, Inc. announced that they will report Q2, 2021 results on Aug 04, 2021
IVERIC bio, Inc., Q2 2021 Earnings Call, Aug 04, 2021
2021-07-28 12:00:00
IVERIC bio, Inc., Q2 2021 Earnings Call, Aug 04, 2021
IVERIC bio, Inc. Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura Ahead of Schedule
2021-07-26 11:30:00
IVERIC bio, Inc. announced the early completion of patient enrollment of GATHER2, the company’s second pivotal clinical trial of Zimura (avacincaptad pegol) in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Company expects topline GATHER2 data to be become available during the second half of 2022, approximately one year after the enrollment of the last patient, plus the time needed for database lock and analysis. In June 2021, the Company announced that it is targeting patient retention for the trial, as measured by the injection fidelity rate through month 12, of greater than 90%. Injection fidelity is calculated by dividing the total number of actual injections by the total number of expected injections based on the number of enrolled patients. The Company considers injection fidelity to be the most important component of patient retention because it reflects the timely administration of the drug into the patient’s eye. The Company also announced earlier this month that it received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the overall design of GATHER2. The agreement further solidifies the Company’s plans to file an application with the FDA for marketing approval of Zimura for GA secondary to AMD, if the ongoing GATHER2 clinical trial meets its primary endpoint at 12 months. Zimura met its pre-specified primary efficacy endpoint at 12 months and reached statistical significance in the previously completed GATHER1 pivotal clinical trial. In GATHER2, 448 patients were randomized to receive either monthly administration of Zimura 2 mg or sham during the first 12 months of the trial, at which time the primary efficacy analysis of the mean rate of change of GA growth (slope) at 12 months will be performed. If the 12 month results are positive, the Company plans to file an application with the U.S. Food and Drug Administration and the European Medicines Agency for marketing approval of Zimura for GA following receipt of that data. At month 12, the Company plans to re-randomize patients in the Zimura 2 mg arm to receive either monthly or every other month administration of Zimura 2 mg. The final evaluation will take place at month 24.
IVERIC bio, Inc. Appoints Christopher Simms as Senior Vice President and Chief Commercial Officer, Effective August 2, 2021
2021-07-19 11:30:00
IVERIC bio, Inc. announced the appointment of Christopher Simms to Senior Vice President and Chief Commercial Officer, effective August 2, 2021. Mr. Simms joins Iveric Bio from Novartis, where he successfully managed commercial operations for the U.S. Ophthalmics Franchise, launching BEOUV® (brolucizumab injection) for wet age-related macular degeneration (AMD). Before Novartis, he served as marketing lead for the Genentech ophthalmology business which included creating a new brand positioning and launching a new campaign for Lucentis (ranibizumab injection). Mr. Simms is an accomplished healthcare leader with more than 20 years of diverse commercial leadership experience at Johnson & Johnson, Genentech and Novartis, including focused experience in retina, ophthalmology and optometry. Most recently, he was the Vice President and Head of the Novartis US Ophthalmics business unit which includes the brands BEOVU and Xiidra. He joined Novartis in 2017 to build the commercial launch strategy for BEOUV after leading commercial efforts on Lucentis at Genentech. Prior to Genentech, he spent 16 years at Johnson & Johnson working with leading brands across their vision care, diabetes and consumer goods businesses in Canada, Japan and the US.
H.C. Wainwright & Co., LLC, H.C. Wainwright 2021 Virtual Ophthalmology Investor Conference, Aug 17, 2021
2021-07-15 14:11:00
H.C. Wainwright & Co., LLC, H.C. Wainwright 2021 Virtual Ophthalmology Investor Conference, Aug 17, 2021.
IVERIC Bio, Inc. Provides Updates on Clinical Trails
2021-07-12 20:01:00
IVERIC bio, Inc. provided the following updates relating to its business. GATHER2 Enrollment: The Company is expecting to enroll approximately 440 patients in GATHER2, its ongoing Phase 3 clinical trial evaluating Zimura® (avacincaptad pegol) for the treatment of geographic atrophy secondary to age-related macular degeneration, and it expects to complete patient enrollment during the week beginning July 19, 2021. The Company expects top-line data from GATHER2 to become available during the second half of 2022, approximately one year after the enrollment of the last patient plus the time needed for database lock and analysis. IC-200: The Company has completed a preclinical toxicology study of IC-200, the Company's gene therapy product candidate for BEST1 -related inherited retinal diseases, in a naturally occurring canine disease model of Best disease. Subject to regulatory review, the Company plans to initiate a Phase 1/2 clinical trial of IC-200 during the fourth quarter of 2021. The first IC-200 clinical trial will focus on patients with the autosomal recessive form of the disease, autosomal recessive bestrophinopathy. IC-100: As previously disclosed, the Company was planning to discuss with the U.S. Food and Drug Administration, or FDA, the results from its toxicology studies of IC-100, the Company's gene therapy product candidate for rhodopsin-mediated autosomal dominant retinitis pigmentosa, and the design of its first-in-human clinical trial, before submitting an investigational new drug application, or IND. The FDA advised, in lieu of this meeting, additional discussion should be conducted during the 30-day IND review period following IND submission. The Company is considering its development options for this product candidate. Massachusetts Lab Space and Minigene Programs: The Company recently hired four individuals who were previously at the University of Massachusetts Medical School, UMMS, including the principal investigator for the Company's miniCEP290, miniABCA4 and miniUSH2A sponsored research programs at UMMS. The Company is working to transition the research and preclinical development activities for these programs from UMMS to the Company. The Company is also preparing to establish laboratory space for these employees to continue working on these programs and other preclinical research and development activities for the Company.
IVERIC bio, Inc. has filed a Follow-on Equity Offering.
2021-07-12 00:00:00
IVERIC bio, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock
IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $100.19 million.
2021-07-12 00:00:00
IVERIC bio, Inc. has completed a Follow-on Equity Offering in the amount of $100.19 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 11,650,000 Price\Range: $8.6 Discount Per Security: $0.516
Certain Common Stock of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 11-SEP-2021.
2021-07-12 00:00:00
Certain Common Stock of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 11-SEP-2021. These Common Stock will be under lockup for 61 days starting from 12-JUL-2021 to 11-SEP-2021. Details: The company's directors and officers have agreed that, without the prior written consent of Cowen and Company, LLC and Credit Suisse Securities (USA) LLC on behalf of the underwriters, will not, during the period ending 60 days after the date of this prospectus, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned or any securities so owned convertible into or exercisable or exchangeable for shares of common stock; enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock; or publicly disclose the intention to make any such offer, sale, pledge or disposition of shares of common stock; whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise.
Certain Stock Options of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 11-SEP-2021.
2021-07-12 00:00:00
Certain Stock Options of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 11-SEP-2021. These Stock Options will be under lockup for 61 days starting from 12-JUL-2021 to 11-SEP-2021. Details: The company's directors and officers have agreed that, without the prior written consent of Cowen and Company, LLC and Credit Suisse Securities (USA) LLC on behalf of the underwriters, will not, during the period ending 60 days after the date of this prospectus, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned or any securities so owned convertible into or exercisable or exchangeable for shares of common stock; enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock; or publicly disclose the intention to make any such offer, sale, pledge or disposition of shares of common stock; whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise.
Certain Restricted Stock Units of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 11-SEP-2021.
2021-07-12 00:00:00
Certain Restricted Stock Units of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 11-SEP-2021. These Restricted Stock Units will be under lockup for 61 days starting from 12-JUL-2021 to 11-SEP-2021. Details: The company's directors and officers have agreed that, without the prior written consent of Cowen and Company, LLC and Credit Suisse Securities (USA) LLC on behalf of the underwriters, will not, during the period ending 60 days after the date of this prospectus, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned or any securities so owned convertible into or exercisable or exchangeable for shares of common stock; enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock; or publicly disclose the intention to make any such offer, sale, pledge or disposition of shares of common stock; whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise.
Certain Warrants of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 11-SEP-2021.
2021-07-12 00:00:00
Certain Warrants of IVERIC bio, Inc. are subject to a Lock-Up Agreement Ending on 11-SEP-2021. These Warrants will be under lockup for 61 days starting from 12-JUL-2021 to 11-SEP-2021. Details: The company's directors and officers have agreed that, without the prior written consent of Cowen and Company, LLC and Credit Suisse Securities (USA) LLC on behalf of the underwriters, will not, during the period ending 60 days after the date of this prospectus, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned or any securities so owned convertible into or exercisable or exchangeable for shares of common stock; enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock; or publicly disclose the intention to make any such offer, sale, pledge or disposition of shares of common stock; whether any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise.
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021
2021-07-08 08:44:00
Stifel, Nicolaus & Company, Incorporated, Stifel 2021 Virtual Healthcare Conference, Nov 15, 2021 through Nov 17, 2021. Venue: New York, New York, United States.
IVERIC bio, Inc. - Special Call
2021-07-06 10:00:00
To discuss the announcement of receiving written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the overall design of GATHER2, the Company’s pivotal clinical trial of Zimura
IVERIC bio, Inc. Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
2021-07-06 10:00:00
IVERIC bio, Inc. announced that the company received written agreement from the U.S. Food and Drug Administration under a Special Protocol Assessment for the overall design of GATHER2, the company’s pivotal clinical trial of Zimura® (avacincaptad pegol) in development for the treatment of geographic atrophy secondary to age-related macular degeneration. As previously announced, the company expects to complete enrollment in GATHER2 in late July of this year. Based on this timeline, the company expects topline GATHER2 data to be available in the second half of 2022, approximately one year after the enrollment of the last patient plus the time needed for database lock and analysis. Similar to the company’s completed GATHER1 clinical trial, GATHER2 is designed to be an adequate and well-controlled clinical trial which, if positive, would support a New Drug Application for Zimura in the treatment of GA secondary to AMD. The SPA agreement further solidifies the Company’s plans to file an application with the FDA if the ongoing GATHER2 clinical trial meets its primary efficacy endpoint at 12 months. In connection with the SPA, the FDA recommended, and the Company accepted, modifying the primary efficacy endpoint for the GATHER2 trial from the mean rate of change in GA area over 12 months measured by fundus autofluorescence at three timepoints: baseline, month 6 and month 12, to the mean rate of growth (slope) estimated based on GA area measured by FAF in at least three timepoints: baseline, month 6 and month 12. In connection with the SPA, the Company submitted, and the FDA reviewed, a revised clinical trial protocol and statistical analysis plan (SAP) for the GATHER2 trial reflecting the revised primary efficacy endpoint and agreed upon statistical analysis method. The original primary efficacy endpoint estimated the mean rate of change in GA area from baseline to month 12, as measured by FAF readings at three time points (baseline, month 6 and month 12), without assuming a constant rate of growth over the period. Using the same raw data, the FDA preferred method estimates the mean rate of growth of GA area from baseline to month 12, based on FAF readings at the same three time points (baseline, month 6 and month 12), assuming a constant rate of growth over the period, essentially fitting a straight line based on the data. In parallel discussions with those for the GATHER2 SPA, the FDA indicated to the Company that, as part of a future NDA submission for Zimura, the GATHER1 results will be considered using the original prespecified primary efficacy endpoint analysis, together with a post-hoc analysis using the same FDA preferred method that will be used for the GATHER2 trial (mean rate of growth (slope) estimated based on GA area measured by FAF in the relevant timepoints).
Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021
2021-06-29 20:28:00
Wedbush Securities Inc., 12th Annual Wedbush PacGrow Healthcare Virtual Conference, Aug 10, 2021 through Aug 11, 2021.
Fundamental Summary
At a high level, the metrics from IVERIC bio's Q1 financial report release were demonstrably negative. Specifically, their income and value factors indicate an execution challenge when it comes to generating exciting and consistent performance. These results suggest a challenging future for IVERIC bio's stock. We gave IVERIC bio a 54 rating and a UNDERPERFORM recommendation.
IVERIC bio reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 34.54 million compared to USD 26.8 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.29 a year ago. Diluted loss per share from continuing operations was USD 0.29 compared to USD 0.29 a year ago.
Business Description
IVERIC bio, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Sector Overview
IVERIC bio is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. IVERIC bio's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -48.9 | -17.8% | 79 | |
| Net Cashflow | 162.5 | -16.7% | 64 | |
| Capital Expenditure | -0.5 | -32.1% | 44 | |
| Asset Turnover | 0.0 | 0.0% | 71 | |
| Free Cashflow | -1.0 | -1.9% | 67 |
* All values are TTM
The below chart reflects IVERIC bio's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While IVERIC bio's peer average final assessment score stands on 63.0, IVERIC bio's score is 54.
- ISEE
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. IVERIC bio's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), IVERIC bio's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 47.
5D MA
9.95
50D MA
11.65
200D MA
14.75
MACD
-0.48
RSI
29.59
STOCH
19.25
Balance Sheet Analysis
Several numbers from IVERIC bio's current balance sheet were concerning, in two areas in particular: Equity and Book Value Factors. IVERIC bio reported weak equity changes momentum this period. At filing, equity was reported as 333.2, representing -7.6% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Therefore, their equity movement component earned a score of 46. Also, IVERIC bio's price to book ratio (P/B) was reported as 3.5 and represents -35.3% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. The company's book value factors were lackluster and showed that management hasn't figured out how to overperform expectations. Consequently, their book value factors movement received a grade of 48. On the other hand, Assets, jumped out as looking rather positive. The company's assets section could set high expectations for IVERIC bio's future attractiveness, as they went to 352.7, which is a -9.4% change from the last period. This performance is interesting in comparison to its peers and competitors. The company's asset component, therefore, received a grade of 67. Therefore, it received a cautionary score of 50.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 352.7 | -9.4% | 67 |
| Liabilities | 19.6 | -32.2% | 50 |
| Price to Book | 3.5 | -35.3% | 48 |
| Cash & Equivalents | 191.9 | -26.6% | 48 |
| Equity | 333.2 | -7.6% | 46 |
The below chart describes IVERIC bio's performance as reflected on its balance sheet with respect to its peers. While IVERIC bio received a balance sheet score of 50, the average of its peers stands on 62.0.
- ISEE
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 16 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 18 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 20 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 23 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 38 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
IVERIC bio appears likely to maintain its strong income statement metrics and momentum going forward. IVERIC bio reported highly encouraging numbers for its revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. The company's revenue efficiency, therefore, received a grade of 84. Also, IVERIC bio's reported return on equity (ROE) ratio was -48.9, representing a change of -17.8%. Its return factor metrics are even more remarkable when compared to their peers. Consequently, their return factors received a grade of 79. That said, one metric, EBITDA, stood out as strongly negative. IVERIC bio's EBIDTA now sits at -121.8 and represents -6.8% change from the last reporting period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. Their EBITDA metrics are even more problematic when compared to their peers. Therefore, their EBITDA component earned a score of 58. Its income statement, therefore, earned a score of 70.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -121.8 | -6.8% | 58 |
| Total Revenues | 0.0 | 0.0% | 84 |
| Return on Equity | -48.9 | -17.8% | 79 |
The below chart describes IVERIC bio's performance as reflected on its income statement with respect to its peers. While IVERIC bio received a income statement score of 70 , the average of its peers stands on 68.0.
- ISEE
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 16 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 18 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 23 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 38 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Overall, IVERIC bio's critical cash flow metrics appear to signal strong support and a high likelihood of positive growth going forward. IVERIC bio is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.0, representing a 0.0% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. Correspondingly, their asset turnover movement received a grade of 71. Also, IVERIC bio did a great job related to free cash flow this period, which stood at -1.0, representing a -1.9% change from the previous filing. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. The company's free cash flow metrics are especially strong compared to its peers. Management seems to balance cash flow management, asset growth, and resource allocations in general. The company's free cash flow movement, therefore, received a grade of 67. However, one discouraging result, Capital Expenditure, stood out. IVERIC bio's management was ineffective in materially improving CapEx, which now sits at -0.5 and represents a -32.1% change from the previous report. This performance is all the more uninspiring relative to their peers and competitors. Consequently, their CapEx movement received a grade of 44. Therefore, their cash flow earned a grade of 64.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | 162.5 | -16.7% | 64 |
| Capital Expenditure | -0.5 | -32.1% | 44 |
| Asset Turnover | 0.0 | 0.0% | 71 |
| Free Cashflow | -1.0 | -1.9% | 67 |
The below chart describes IVERIC bio's performance as reflected on its cash flow with respect to its peers. While IVERIC bio received a cash flow score of 64, the average of its peers stands on 68.0.
- ISEE
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 16 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 18 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 23 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 30 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 31 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 32 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 33 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 34 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 35 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 36 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 37 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 38 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 39 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 40 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 41 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 42 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.